These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 20510316)
61. Influence of cholesterol on liposome stability and on in vitro drug release. Briuglia ML; Rotella C; McFarlane A; Lamprou DA Drug Deliv Transl Res; 2015 Jun; 5(3):231-42. PubMed ID: 25787731 [TBL] [Abstract][Full Text] [Related]
62. Preparation, characterization and in vivo pharmacokinetic study of PVP-modified oleanolic acid liposomes. Liu Y; Luo X; Xu X; Gao N; Liu X Int J Pharm; 2017 Jan; 517(1-2):1-7. PubMed ID: 27899320 [TBL] [Abstract][Full Text] [Related]
63. Multivesicular liposome (MVL) sustained delivery of a novel synthetic cationic GnRH antagonist for prostate cancer treatment. Wang T; Gao L; Quan D J Pharm Pharmacol; 2011 Jul; 63(7):904-10. PubMed ID: 21635255 [TBL] [Abstract][Full Text] [Related]
64. Comparison of the interaction of doxorubicin, daunorubicin, idarubicin and idarubicinol with large unilamellar vesicles. Circular dichroism study. Gallois L; Fiallo M; Garnier-Suillerot A Biochim Biophys Acta; 1998 Mar; 1370(1):31-40. PubMed ID: 9518541 [TBL] [Abstract][Full Text] [Related]
65. Drug-drug interactions arising from the use of liposomal vincristine in combination with other anticancer drugs. Waterhouse DN; Dos Santos N; Mayer LD; Bally MB Pharm Res; 2001 Sep; 18(9):1331-5. PubMed ID: 11683249 [No Abstract] [Full Text] [Related]
67. Targeted delivery of epirubicin to tumor-associated macrophages by sialic acid-cholesterol conjugate modified liposomes with improved antitumor activity. Zhou S; Zhang T; Peng B; Luo X; Liu X; Hu L; Liu Y; Di D; Song Y; Deng Y Int J Pharm; 2017 May; 523(1):203-216. PubMed ID: 28336455 [TBL] [Abstract][Full Text] [Related]
69. Development of a stable single-vial liposomal formulation for vincristine. Mao W; Wu F; Lee RJ; Lu W; Wang J Int J Nanomedicine; 2019; 14():4461-4474. PubMed ID: 31296986 [No Abstract] [Full Text] [Related]
70. An In Vitro Evaluation of Four Types of Drug-Eluting Embolics Loaded with Idarubicin. Guiu B; Hincapie G; Thompson L; Wu Y; Boulin M; Cassinotto C; Cruise GM J Vasc Interv Radiol; 2019 Aug; 30(8):1303-1309. PubMed ID: 31155500 [TBL] [Abstract][Full Text] [Related]
71. Elastic liposomes as carriers for oral delivery and the brain distribution of (+)-catechin. Huang YB; Tsai MJ; Wu PC; Tsai YH; Wu YH; Fang JY J Drug Target; 2011 Sep; 19(8):709-18. PubMed ID: 21303222 [TBL] [Abstract][Full Text] [Related]
72. Liposomes modified with superhydrophilic polymer linked to a nonphospholipid anchor exhibit reduced complement activation and enhanced circulation. Nag OK; Yadav VR; Croft B; Hedrick A; Awasthi V J Pharm Sci; 2015 Jan; 104(1):114-23. PubMed ID: 25393628 [TBL] [Abstract][Full Text] [Related]
73. Pulmonary liposomal formulations encapsulated procaterol hydrochloride by a remote loading method achieve sustained release and extended pharmacological effects. Tahara K; Tomida H; Ito Y; Tachikawa S; Onodera R; Tanaka H; Tozuka Y; Takeuchi H Int J Pharm; 2016 May; 505(1-2):139-46. PubMed ID: 27012982 [TBL] [Abstract][Full Text] [Related]
74. RGD-modified liposomes enhance efficiency of aclacinomycin A delivery: evaluation of their effect in lung cancer. Feng C; Li X; Dong C; Zhang X; Zhang X; Gao Y Drug Des Devel Ther; 2015; 9():4613-20. PubMed ID: 26316700 [TBL] [Abstract][Full Text] [Related]
75. [Preparation conditions optimization of Epimedium polysaccharide liposome]. Gao H; Gao Q; Wang DY; Fan YP; Guo LW; Zhao XN Zhong Yao Cai; 2011 Sep; 34(9):1429-33. PubMed ID: 22260012 [TBL] [Abstract][Full Text] [Related]
76. pH gradient loading of anthracyclines into cholesterol-free liposomes: enhancing drug loading rates through use of ethanol. Dos Santos N; Cox KA; McKenzie CA; van Baarda F; Gallagher RC; Karlsson G; Edwards K; Mayer LD; Allen C; Bally MB Biochim Biophys Acta; 2004 Feb; 1661(1):47-60. PubMed ID: 14967474 [TBL] [Abstract][Full Text] [Related]
77. New drug delivery nanosystem combining liposomal and dendrimeric technology (liposomal locked-in dendrimers) for cancer therapy. Gardikis K; Hatziantoniou S; Bucos M; Fessas D; Signorelli M; Felekis T; Zervou M; Screttas CG; Steele BR; Ionov M; Micha-Screttas M; Klajnert B; Bryszewska M; Demetzos C J Pharm Sci; 2010 Aug; 99(8):3561-71. PubMed ID: 20564386 [TBL] [Abstract][Full Text] [Related]
78. Ammonium sulfate gradient loading of brucine into liposomes: effect of phospholipid composition on entrapment efficiency and physicochemical properties in vitro. Chen J; Lin A; Chen Z; Wang W; Zhang T; Cai H; Cai B Drug Dev Ind Pharm; 2010 Mar; 36(3):245-53. PubMed ID: 19678739 [TBL] [Abstract][Full Text] [Related]
79. Efficient human breast cancer xenograft regression after a single treatment with a novel liposomal formulation of epirubicin prepared using the EDTA ion gradient method. Gubernator J; Lipka D; Korycińska M; Kempińska K; Milczarek M; Wietrzyk J; Hrynyk R; Barnert S; Süss R; Kozubek A PLoS One; 2014; 9(3):e91487. PubMed ID: 24621591 [TBL] [Abstract][Full Text] [Related]
80. Liposomal solubilization of new 3-hydroxy-quinolinone derivatives with promising anticancer activity: a screening method to identify maximum incorporation capacity. di Cagno M; Styskala J; Hlaváč J; Brandl M; Bauer-Brandl A; Skalko-Basnet N J Liposome Res; 2011 Dec; 21(4):272-8. PubMed ID: 21323606 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]